Novo Holdings, the parent organisation of Danish drugmaker Novo Nordisk, has completed its previously announced acquisition of Catalent for a total enterprise value of $16.5bn.
Catalent is a contract development and manufacturing organisation (CDMO) that develops and produces pre-filled syringes and orally disintegrating tablets for pharma companies.
In February this year, Novo Holdings signed an agreement to acquire Catalent, which also includes the acquisition of Novo Holdings’ three fill-finish sites by Novo Nordisk.
The three fill-finish sites acquired from Novo Holdings are located in Anagni, Italy; Bloomington, US; and Brussels, Belgium.
Recently, Catalent and Novo Holdings announced that all regulatory conditions for their pending transaction have been met.
The announcement follows the Catalent stockholders’ voting, and the European Commission (EC) unconditional antitrust approval for the transaction.
Novo Holdings senior partner Jonathan Levy said: “With our deep experience in the life sciences sector, Novo Holdings sees a significant opportunity to support Catalent’s continued commercial success, driving future growth while benefitting patients around the world.”
Catalent president and CEO Alessandro Maselli said: “As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver better outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders.”
Novo Holdings CEO Kasim Kutay said: “Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”
In a separate development, Novo Holdings has led a $100m Series C financing of SiteOne Therapeutics, a biopharmaceutical company developing non-opioid pain therapeutics.
The US-based biopharmaceutical company will use the financing to support the advancement of its portfolio through human clinical proof of concept.
OrbiMed, Wellington Management, Mission BioCapital, and BSQUARED Capital, also participated in the financing round, alongside existing investors.
As part of the transaction, Novo Holdings US venture investments senior partner Ken Harrison will join the SiteOne Therapeutics Board of Directors.
Ken Harrison said: “SiteOne Therapeutics’ portfolio of selective ion channel modulators holds immense promise for the non-opioid treatment of pain.
“This investment reflects our confidence in the Company’s underlying science and our regard for its mission of transforming pain management for the millions of patients living with chronic pain in the US and around the globe.”
SiteOne Therapeutics president and CEO John Mulcahy said: “This funding will enable human proof of concept studies on our isoform-selective sodium channel inhibitors and development of other ion channel modulators.”
